
## Antonio D'alessio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6780928/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	27.8	649
2	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€Pugh A and B cirrhosis: A realâ€world study. Hepatology, 2022, 76, 1000-1012.	7.3	114
3	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 397-409.	3.7	59
4	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports, 2021, 3, 100347.	4.9	57
5	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	3.7	44
6	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	2.8	42
7	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2022, 22, 253-264.	3.1	20
8	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897.	3.7	17
9	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Current Opinion in Oncology, 2021, 33, 386-394.	2.4	13
10	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
11	Outcome of liver cancer patients with SARS oVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
12	New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. Chemotherapy, 2022, 67, 164-172.	1.6	10
13	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 177-191.	3.7	9
14	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	2.4	9
15	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 401-413.	4.1	9
16	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opinion on Investigational Drugs, 2022, 31, 681-691.	4.1	7
17	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs and Aging, 2021, 38, 579-591.	2.7	5
18	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	3.7	5

ANTONIO D'ALESSIO

#	Article	IF	CITATIONS
19	Treating patients with advanced hepatocellular carcinoma and impaired liver function: Broadening the reach of antiâ€cancer therapy. Liver Cancer International, 2021, 2, 31-32.	1.3	4
20	COVIDâ€19 and liver cancer clinical trials: Not everything is lost. Liver International, 2020, 40, 1541-1544.	3.9	3
21	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. Journal of Personalized Medicine, 2022, 12, 204.	2.5	3
22	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 425-435.	4.1	3
23	A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL Journal of Clinical Oncology, 2022, 40, e16195-e16195.	1.6	3
24	Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 5-6.	1.3	1
25	Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.8	1
26	Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	1.3	0
27	Reply. Hepatology, 2022, 76, E82-E83.	7.3	0